Brookline Cap M reissued their buy rating on shares of Proteon Therapeutics (NASDAQ:PRTO) in a report released on Tuesday.
Other equities analysts also recently issued research reports about the company. HC Wainwright upgraded Proteon Therapeutics from a neutral rating to a buy rating and set a $3.00 target price on the stock in a research note on Thursday, May 10th. ValuEngine upgraded Proteon Therapeutics from a sell rating to a hold rating in a research note on Saturday, June 2nd. Cowen restated a hold rating on shares of Proteon Therapeutics in a research note on Thursday, May 10th. Robert W. Baird set a $3.00 target price on Proteon Therapeutics and gave the stock a hold rating in a research note on Wednesday, March 14th. Finally, Zacks Investment Research upgraded Proteon Therapeutics from a sell rating to a hold rating in a research note on Tuesday, March 13th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $2.83.
Proteon Therapeutics stock opened at $2.55 on Tuesday. The company has a market capitalization of $43.30 million, a P/E ratio of -1.20 and a beta of 1.52. Proteon Therapeutics has a 12 month low of $1.25 and a 12 month high of $2.90.
Proteon Therapeutics (NASDAQ:PRTO) last announced its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.03. equities analysts expect that Proteon Therapeutics will post -1.39 EPS for the current year.
An institutional investor recently raised its position in Proteon Therapeutics stock. Renaissance Technologies LLC boosted its position in Proteon Therapeutics Inc (NASDAQ:PRTO) by 17.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 201,500 shares of the biopharmaceutical company’s stock after purchasing an additional 29,600 shares during the period. Renaissance Technologies LLC owned about 1.14% of Proteon Therapeutics worth $383,000 as of its most recent SEC filing. Institutional investors own 50.60% of the company’s stock.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc, a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to improve hemodialysis vascular access outcomes.
Receive News & Ratings for Proteon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.